Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these tre...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-17703-6 |
| id |
doaj-e2e3c987d9e84ccb9b7c66bef2e582d6 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
David Simon Koray Tascilar Gerhard Krönke Arnd Kleyer Mario M. Zaiss Franz Heppt Christine Meder Raja Atreya Entcho Klenske Peter Dietrich Abdullah Abdullah Thorsten Kliem Giulia Corte Harriet Morf Moritz Leppkes Andreas E. Kremer Andreas Ramming Milena Pachowsky Florian Schuch Monika Ronneberger Stefan Kleinert Clara Maier Axel J. Hueber Karin Manger Bernhard Manger Carola Berking Matthias Tenbusch Klaus Überla Michael Sticherling Markus F. Neurath Georg Schett |
| spellingShingle |
David Simon Koray Tascilar Gerhard Krönke Arnd Kleyer Mario M. Zaiss Franz Heppt Christine Meder Raja Atreya Entcho Klenske Peter Dietrich Abdullah Abdullah Thorsten Kliem Giulia Corte Harriet Morf Moritz Leppkes Andreas E. Kremer Andreas Ramming Milena Pachowsky Florian Schuch Monika Ronneberger Stefan Kleinert Clara Maier Axel J. Hueber Karin Manger Bernhard Manger Carola Berking Matthias Tenbusch Klaus Überla Michael Sticherling Markus F. Neurath Georg Schett Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion Nature Communications |
| author_facet |
David Simon Koray Tascilar Gerhard Krönke Arnd Kleyer Mario M. Zaiss Franz Heppt Christine Meder Raja Atreya Entcho Klenske Peter Dietrich Abdullah Abdullah Thorsten Kliem Giulia Corte Harriet Morf Moritz Leppkes Andreas E. Kremer Andreas Ramming Milena Pachowsky Florian Schuch Monika Ronneberger Stefan Kleinert Clara Maier Axel J. Hueber Karin Manger Bernhard Manger Carola Berking Matthias Tenbusch Klaus Überla Michael Sticherling Markus F. Neurath Georg Schett |
| author_sort |
David Simon |
| title |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_short |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_full |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_fullStr |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_full_unstemmed |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_sort |
patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of sars-cov-2 seroconversion |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2020-07-01 |
| description |
Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19. |
| url |
https://doi.org/10.1038/s41467-020-17703-6 |
| work_keys_str_mv |
AT davidsimon patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT koraytascilar patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT gerhardkronke patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT arndkleyer patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT mariomzaiss patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT franzheppt patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT christinemeder patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT rajaatreya patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT entchoklenske patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT peterdietrich patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT abdullahabdullah patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT thorstenkliem patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT giuliacorte patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT harrietmorf patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT moritzleppkes patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT andreasekremer patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT andreasramming patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT milenapachowsky patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT florianschuch patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT monikaronneberger patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT stefankleinert patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT claramaier patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT axeljhueber patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT karinmanger patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT bernhardmanger patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT carolaberking patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT matthiastenbusch patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT klausuberla patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT michaelsticherling patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT markusfneurath patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT georgschett patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion |
| _version_ |
1721282914299150336 |
| spelling |
doaj-e2e3c987d9e84ccb9b7c66bef2e582d62021-07-25T11:39:35ZengNature Publishing GroupNature Communications2041-17232020-07-011111710.1038/s41467-020-17703-6Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon0Koray Tascilar1Gerhard Krönke2Arnd Kleyer3Mario M. Zaiss4Franz Heppt5Christine Meder6Raja Atreya7Entcho Klenske8Peter Dietrich9Abdullah Abdullah10Thorsten Kliem11Giulia Corte12Harriet Morf13Moritz Leppkes14Andreas E. Kremer15Andreas Ramming16Milena Pachowsky17Florian Schuch18Monika Ronneberger19Stefan Kleinert20Clara Maier21Axel J. Hueber22Karin Manger23Bernhard Manger24Carola Berking25Matthias Tenbusch26Klaus Überla27Michael Sticherling28Markus F. Neurath29Georg Schett30Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenRheumatology Clinical Practice ErlangenRheumatology Clinical Practice ErlangenRheumatology Clinical Practice ErlangenInstitute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenRheumatology Practice BambergDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenInstitute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenInstitute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDeutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum ErlangenDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum ErlangenCytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.https://doi.org/10.1038/s41467-020-17703-6 |